Meeting
2024 ASCO Annual Meeting
Rapid reduction of free light chains and improvement in renal outcomes in patients with newly diagnosed multiple myeloma admitted with acute kidney injury with daratumumab-based therapy and without plasmapheresis.
Authors
E. Bridget Kim
Massachusetts General Hospital Cancer Center, Boston, MA
E. Bridget Kim , Jack Malespini , Matthew Lei , Andrew Robert Branagan , Diana Cirstea , Samuel S Han , Cole W Minsky , Noopur S. Raje , Andrew J Yee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 7525)
DOI
10.1200/JCO.2024.42.16_suppl.7525
Abstract #
7525
Poster Bd #
162
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA.
First Author: Robert M. Rifkin
Poster
2021 ASCO Annual Meeting
KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma.
First Author: Saad Z. Usmani
Poster
2023 ASCO Annual Meeting
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
First Author: Cyrille Touzeau
Poster
2022 ASCO Annual Meeting
Updated survival with extended follow-up on patients with newly diagnosed multiple myeloma treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy and a risk-stratified maintenance approach.
First Author: Rujul H Parikh